Join date: Jun 28, 2018
Nov 3, 2021 ∙ 3 min
FDA Grants Profounda Orphan DD Approval for treatment of invasive candidiasis with Miltefosine
FDA Grants Profounda Orphan Drug Designation Approval for treatment of invasive candidiasis with Miltefosine - Invasive candidiasis is an...
Oct 6, 2017 ∙ 1 min
ID WEEK in SAN DIEGO
The Profounda team had a booth at this years ID Week convention. Thanks to those that stopped by to learn more about Impavido
Impavido® (miltefosine) is an FDA-approved treatment for cutaneous, mucosal and visceral leishmaniasis in patients 12 years of age and older. PLEASE SEE FULL PRESCRIBING INFO